Figure 10.

Relative abundance of HCPs identified in a drug candidate from different processes of development, FIH platform process (blue), intermediate process development (red), and commercially enabling process (green)

Relative abundance of HCPs identified in a drug candidate from different processes of development, FIH platform process (blue), intermediate process development (red), and commercially enabling process (green)